Advances in targeted therapy for malignant lymphoma

Area of Science:

• Oncology
• Hematology
• Cancer Therapeutics

Background:

• Lymphoma incidence is rising globally, ranking among the top ten cancers.
• While targeted therapies improve outcomes for some, refractory and relapsed lymphoma remain difficult to treat.
• Significant research is ongoing to identify new therapeutic targets and strategies.

Purpose of the Study:

• To systematically review advances in targeted therapy for malignant lymphoma.
• To provide a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.

Main Methods:

• Comprehensive literature review of targeted therapeutic strategies for lymphoma.
• Analysis of novel antibodies, small molecular inhibitors, immune checkpoint inhibitors, and CAR T-cell therapies.
• Evaluation of clinical data and research on targeted agents and their impact on the tumor microenvironment.

Main Results:

• Targeted agents including novel antibodies and small molecule inhibitors show promise.
• Immune checkpoint inhibitors and CAR T-cells represent rapidly developing strategies targeting the tumor microenvironment.
• Despite successes, adverse events require careful consideration, and optimal treatment selection, dosage, and combinations need further study.

Conclusions:

• Precision medicine offers a framework for mechanism-based lymphoma treatment.
• Continued research is crucial to optimize targeted therapies and overcome challenges in refractory and relapsed lymphoma.
• Further investigation into candidate selection, dosage, and combination therapies is warranted for improved patient outcomes.